Zura Bio (NASDAQ:ZURA) Releases Quarterly Earnings Results

Zura Bio (NASDAQ:ZURA) released its quarterly earnings results on Thursday. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05), FiscalAI reports.

Zura Bio Stock Down 7.2%

Shares of NASDAQ:ZURA traded down $0.35 during midday trading on Thursday, reaching $4.54. The company’s stock had a trading volume of 976,506 shares, compared to its average volume of 627,273. The firm has a market cap of $430.76 million, a price-to-earnings ratio of -4.28 and a beta of 0.09. Zura Bio has a 1 year low of $0.98 and a 1 year high of $7.44. The business has a 50 day moving average price of $5.94 and a 200 day moving average price of $5.16.

Insider Buying and Selling

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was purchased at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the completion of the transaction, the insider owned 6,552,725 shares of the company’s stock, valued at approximately $40,954,531.25. This trade represents a 43.93% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 14.23% of the company’s stock.

Institutional Trading of Zura Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. Scientech Research LLC purchased a new position in shares of Zura Bio in the 3rd quarter worth $45,000. Dimensional Fund Advisors LP purchased a new stake in Zura Bio during the fourth quarter valued at about $123,000. Squarepoint Ops LLC acquired a new stake in Zura Bio during the third quarter worth about $109,000. Qube Research & Technologies Ltd purchased a new position in shares of Zura Bio in the 3rd quarter worth about $138,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Zura Bio in the 4th quarter valued at about $192,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZURA has been the subject of a number of analyst reports. Chardan Capital boosted their price target on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Wedbush initiated coverage on shares of Zura Bio in a research note on Monday, February 9th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Oppenheimer decreased their price target on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.